ypertension affects approximately one third of adults in the United States and is a well-recognized risk factor for stroke, coronary artery disease, and renal failure. Although essential (primary) hypertension is the most prevalent form of hypertension, its root cause and underlying mechanisms remain poorly understood. Elevated sympathetic outflow is clearly associated with the development of essential hypertension in animal models 1-3 and in hypertensive patients.
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ypertension affects approximately one third of adults in the United States and is a well-recognized risk factor for stroke, coronary artery disease, and renal failure. Although essential (primary) hypertension is the most prevalent form of hypertension, its root cause and underlying mechanisms remain poorly understood. Elevated sympathetic outflow is clearly associated with the development of essential hypertension in animal models [1] [2] [3] and in hypertensive patients. [4] [5] [6] [7] The paraventricular nucleus (PVN) of the hypothalamus is an important brain region controlling sympathetic outflow. [8] [9] [10] Presympathetic neurons in the PVN project to vasomotor neurons in the rostral ventrolateral medulla (RVLM) in the brain stem and sympathetic preganglionic neurons in the intermediolateral cell column in the spinal cord, which in turn regulate sympathetic nerve discharges. 11, 12 Electrolytic lesion or pharmacological inhibition of the PVN decreases arterial blood pressure (ABP) and sympathetic nerve activity in spontaneously hypertensive rats (SHRs). 1, 2, 13, 14 Also, transplantation of embryonic hypothalamic tissue containing the PVN from SHRs to normotensive rats leads to hypertension in the normal rats. 15, 16 Although hyperactivity of PVN presympathetic neurons is a major source of elevated sympathetic outflow in SHRs, 1,2 the molecular mechanisms responsible for the increased excitability of these neurons are not fully known.
Glutamate is the major excitatory neurotransmitter in the PVN, and increased N-methyl-d-aspartate receptor (NMDAR) activity is critically involved in the augmented sympathetic vasomotor tone in SHRs. 2, 17 The synaptic NMDAR activity of PVN presympathetic neurons is tightly regulated by phosphorylation via serine/threonine kinases and phosphatases, including CK2 (casein kinase II) and calcineurin. [18] [19] [20] In addition, increasing the phosphorylation level of tyrosine residues Abstract-The elevated sympathetic outflow associated with hypertension is maintained by increased N-methyl-d-aspartate receptor (NMDAR) activity in the paraventricular nucleus (PVN) of the hypothalamus. Synaptic NMDAR activity is tightly regulated by protein kinases, including the Src family of tyrosine kinases. We determined whether Src kinases play a role in increased NMDAR activity of PVN neurons projecting to the rostral ventrolateral medulla and in elevated sympathetic vasomotor tone in spontaneously hypertensive rats (SHRs). The Src protein level in the PVN was significantly greater in SHRs than in normotensive Wistar-Kyoto (WKY) rats and was not significantly altered by lowering blood pressure with celiac ganglionectomy in SHRs. Inhibition of Src kinase activity with 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo [3,4-d] pyrimidine (PP2) completely normalized the higher amplitudes of evoked NMDARmediated excitatory postsynaptic currents and puff NMDA-elicited currents of rostral ventrolateral medulla-projecting PVN neurons in SHRs. PP2 treatment also attenuated the higher frequency of NMDAR-mediated miniature excitatory postsynaptic currents of these neurons in SHRs. However, PP2 had no effect on NMDAR-excitatory postsynaptic currents or miniature excitatory postsynaptic currents of rostral ventrolateral medulla-projecting PVN neurons in WKY rats. NMDAR activity increased by an Src-activating peptide was blocked by PP2 but not by inhibition of casein kinase 2. In addition, microinjection of PP2 into the PVN not only decreased lumbar sympathetic nerve discharges and blood pressure but also eliminated the inhibitory effect of the NMDAR antagonist on sympathetic nerve activity and blood pressure in SHRs. Collectively, our findings suggest that increased Src kinase activity potentiates presynaptic and postsynaptic NMDAR activity in the PVN and sympathetic vasomotor tone in hypertension. (Hypertension. 2017;69:154-162.
in NMDARs can increase NMDAR activity. [21] [22] [23] [24] The Src family of nonreceptor protein tyrosine kinases has at least 9 members, and Src is actively expressed in the adult hypothalamus. 25, 26 However, it remains unclear whether the Src kinases contribute to the increased NMDAR activity of PVN presympathetic neurons observed in SHRs.
In the present study, we determined the role of Src kinases in the increased synaptic glutamatergic input to RVLMprojecting PVN neurons in SHRs using in vivo retrograde tracing and in vitro brain slice recordings. We also studied whether Src-mediated NMDAR activity in the PVN is involved in maintaining elevated sympathetic output in SHRs. Our findings suggest that increased Src kinase activity in the PVN plays a pivotal role in the potentiation of pre-and postsynaptic NMDAR activity of PVN presympathetic neurons and in augmented sympathetic outflow in SHRs. Our study provides new insight into the molecular mechanism of the synaptic plasticity associated with sustained sympathetic outflow in hypertension.
Methods

Animal Model
We used male normotensive Wistar-Kyoto (WKY) rats and SHRs (4-and 13-week-old; Harlan, Indianapolis, IN) in the present study. SHRs are the most commonly used and well-characterized animal model of essential hypertension. 27, 28 For the entire study, data were collected from 59 WKY rats and 77 SHRs. The experimental procedures were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center and conformed to the National Institutes of Health guidelines on the ethical use of animals.
The detailed methods for retrograde labeling of PVN neurons, electrophysiological recordings in brain slices, celiac ganglionectomy (CGx), Western blotting, PVN microinjections and lumbar sympathetic nerve recording in vivo, and data analysis are described in the online-only Data Supplement.
Brain Slice Preparation and Recordings
Coronal hypothalamic slices (300-μm thick) containing the PVN were obtained from FluoSphere-injected rats using a vibrating microtome. Whole-cell patch-clamp recordings were performed in labeled neurons in the PVN of the slices ( Figure S1 in the online-only Data Supplement). Excitatory postsynaptic currents (EPSCs) were elicited by electric stimulation through a bipolar tungsten electrode connected to a stimulator. Evoked α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-EPSCs were recorded at a holding potential of −60 mV in the presence of 10 μM bicuculline, and evoked NMDAREPSCs were recorded at a holding potential of +40 mV in the presence of 10 μM bicuculline and 20 μM 6-cyano-7-nitroquinoxaline-2,3-dione. Miniature EPSCs (mEPSCs) were recorded at a holding potential of -60 mV in the presence of 1 μmol/L tetrodotoxin and 10 μmol/L bicuculline. To record postsynaptic NMDAR currents, we puffed NMDA (100 μmol/L) directly onto the recorded neuron at a holding potential of -60 mV. Because NMDARs are voltage-dependently blocked by Mg 2+ at a negative holding potential and coactivated by glycine, puff NMDAinduced currents were recorded in Mg 
Western Immunoblotting
Hypothalamic slices were sectioned 1.08 to 2.12 mm caudal to the bregma, and PVN tissues were micropunched bilaterally with a slice punch. The samples were subjected to 4% to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to a polyvinylidene difluoride membrane, and incubated with a mouse anti-Src antibody (1:1000, catalog no 2578064; Millipore, Bedford, MA) for 24 hours. An ECL kit (ThermoFisher Scientific) was used to detect the Src protein band, which was visualized and quantified with the Odyssey Fc Imager (LI-COR Biosciences, Lincoln, NE) and normalized by the GAPDH protein band on the same blot.
PVN Microinjection and Recording of Lumbar Sympathetic Nerve Activity and ABP
Rats were anesthetized with a mixture of α-chloralose (60-75 mg/kg IP) and urethane (800 mg/kg IP). A small branch of the left lumbar postganglionic sympathetic nerve was isolated under an operating microscope through a retroperitoneal incision. The lumbar sympathetic nerve was cut distally to ensure that afferent activity was not recorded. The lumbar sympathetic nerve activity (LSNA) and ABP were recorded using a 1401-PLUS analog-to-digital converter and Spike2 system (Cambridge Electronic Design, Cambridge, UK). A glass microinjection pipette (tip diameter 20-30 μm) was advanced into the PVN. The location of the pipette tip and diffusion of the drugs in the PVN were determined by including 5% rhodaminelabeled fluorescent microspheres (0.04 μm; Molecular Probes) in the injection solution.
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Data Analysis
Data are presented as mean±SEM. We used the Student's t test or Mann-Whitney U test to determine the significant differences between the 2 groups. One-way analysis of variance with Dunnett's or Tukey's post hoc test was used to determine the significant differences involving more than 2 groups. P<0.05 was considered statistically significant.
Results
SHRs Show Higher Src Protein Level in the PVN
We determined the Src protein levels in the PVN, RVLM, hippocampus, and frontal cortex in WKY rats and SHRs. Western immunoblotting showed a single band of Src proteins in all of the brain tissues, and the total Src protein level in the PVN was significantly greater in SHRs than in WKY rats (n=6 rats in each group; Figure 1A and 1B). In contrast, Src protein levels in the RVLM, hippocampus, and frontal cortex did not differ significantly between WKY rats and SHRs (n=6 rats in each group; Figure 1A and 1B). Furthermore, the Src protein level did not significantly differ between 4-week-old and 13-week-old WKY rats. However, the Src protein level in 13-week-old SHRs was significantly higher than that in 4-week-old SHRs and age-matched WKY rats (n=6 rats in each group; Figure 1C and 1D) .
We then determined whether the higher Src protein level in the PVN of SHRs was a secondary change because of high ABP in SHRs. We performed CGx to lower ABP and then measured Src protein levels in the PVN of SHRs. CGx caused a large reduction in ABP, monitored by telemetry system, in SHRs compared with those subjected to sham surgery. CGx-induced decreases in ABP in SHRs occurred within 5 days after surgery and lasted for at least 2 weeks (Figure 2A and 2B; Figure S2 ). Immunoblotting showed that the Src protein level in the PVN of SHRs did not differ significantly between rats receiving CGx and sham surgery ( Figure 2C and 2D ). In addition, CGx induced a small decrease in ABP in WKY rats (Figure 2A and 2B) . The Src protein level in the PVN was not significantly altered in WKY rats subjected to CGx compared with that in sham-operated WKY rats ( Figure 2C and 2D) . These data suggest that Src upregulation in the PVN is independent of ABP changes in SHRs.
Src Contributes to Increased Postsynaptic NMDAR Currents of PVN Presympathetic Neurons in SHRs
To determine the functional significance of increased Src kinase activity in regulating NMDARs of PVN presympathetic neurons in SHRs, we examined the effects of 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo [3,4-d] pyrimidine (PP2), a highly selective Src kinase inhibitor, [30] [31] [32] on evoked AMPAR-EPSCs and NMDAR-EPSCs in retrograde labeled RVLM-projecting PVN neurons. The hypothalamic slices from WKY rats and SHRs were incubated with either vehicle control (0.05% dimethyl sulfoxide) or PP2 (10 μmol/L) for 1 to 2 hours before electrophysiological recording. PP2 at 10 μmol/L can potently inhibit the Src kinase activity in the hippocampus. 33 The amplitude of evoked NMDAR-EPSCs of labeled PVN neurons was significantly higher in neurons from SHRs than in those from WKY rats in vehicle-treated slices (n=7 neurons in each group; Figure 3A and 3B). PP2 treatment significantly reduced the amplitude of evoked NMDAREPSCs of labeled PVN neurons in SHRs but not in WKY rats (n=7 neurons). However, PP2 treatment did not significantly alter the amplitude of evoked AMPAR-EPSCs of labeled PVN neurons in WKY rats or SHRs (n=7 neurons in each group; Figure 3A and 3B). Also, in vehicle-treated slices, the ratio of NMDAR-EPSCs to AMPAR-EPSCs was significantly higher in SHRs than in WKY rats. PP2 treatment normalized the ratio of NMDAR-EPSCs to AMPAR-EPSCs in SHRs but had no effect on this ratio in WKY rats ( Figure 3C ).
To directly determine the role of Src kinases in the regulation of postsynaptic NMDAR activity, we examined the effect of PP2 on puff NMDA-induced currents in labeled PVN neurons. In vehicle-treated slices, puff application of NMDA (100 μmol/L) induced significantly greater NMDAR currents in SHRs (n=7 neurons) than in WKY rats (n=9 neurons; Figure 3D and 3E). PP2 treatment profoundly reduced NMDAR currents of labeled PVN neurons in SHRs but had no effect on puff NMDA-elicited currents in WKY rats ( Figure 3D and 3E) . These results suggest that increased Src kinase activity critically contributes to the increased postsynaptic NMDAR activity of PVN presympathetic neurons in SHRs.
Src Is Involved in Tonic Activation of Presynaptic NMDARs of PVN Presympathetic Neurons in SHRs
Presynaptic NMDARs in the PVN are latent and not functional in physiological conditions, but they become tonically active to increase synaptic glutamate release in SHRs. 17, 20 To determine whether Src kinases contribute to increased presynaptic NMDAR activity in the PVN in SHRs, we measured the frequency of mEPSCs, which reflects spontaneous quantal release of glutamate from presynaptic terminals. 17, 34 In these experiments, MK-801 (1 mmol/L), an NMDAR channel blocker, was added to the pipette solution to block postsynaptic NMDAR activity. 35 In vehicle-treated slices, the baseline frequency of mEPSCs was significantly higher in SHRs than in WKY rats (n=8 neurons in each group; Figure 4A-4E ), but the baseline amplitude of mEPSCs did not differ significantly between the 2 groups. To confirm that the increase in the frequency of mEPSCs in SHRs was because of increased NMDAR activity, we bath applied the NMDAR antagonist AP5 (50 μmol/L). In vehicle-treated slices, AP5 application significantly reduced the frequency of mEPSCs of labeled PVN neurons of SHRs, but not WKY rats ( Figure 4A-4E) .
PP2 treatment did not significantly change the baseline frequency or amplitude of mEPSCs of labeled PVN neurons in WKY rats. In contrast, treatment with PP2 significantly reduced the frequency of mEPSCs without changing their amplitude in SHRs ( Figure 4A-4F) . Furthermore, bath application of 50 μmol/L AP5 had no effect on the frequency of mEPSCs in SHR brain slices that had been pretreated with PP2 ( Figure 4C-4E ). These data suggest that increased Src kinase activity plays a critical role in the enhanced presynaptic NMDAR activity of PVN presympathetic neurons in SHRs.
CK2 and Src Kinases Are Differentially Involved in the Increased NMDAR Activity of PVN Presympathetic Neurons in SHRs
We have shown previously that CK2, a constitutively active protein serine/threonine kinase, plays a role in increased NMDAR activity of PVN presympathetic neurons in SHRs. 20 To determine whether CK2 and Src kinases play overlapping roles in the control of NMDAR activity in the PVN, we applied (pY)EEI, a synthetic Src-activating peptide, 36,37 through the recording pipette. Intracellular dialysis of (pY)EEI (100 μmol/L) for 15 minutes caused a large increase in NMDA puff-elicited currents in labeled PVN neurons of WKY rats (n=9 neurons; Figure 5A and 5B). In brain slices pretreated with PP2 (10 μmol/L), dialysis of the (pY)EEI peptide failed to significantly alter the NMDA puff-elicited currents in labeled PVN neurons (n=9 neurons). In contrast, in brain slices pretreated with the CK2 inhibitor DRB (5,6-dichloro-1-β-dribofuranosylbenzimidazole; 100 μM), intracellular application of the Src-activating peptide still caused a large increase in NMDA puff-elicited currents in labeled PVN neurons of WKY rats (n=11 neurons; Figure 5A and 5B). Furthermore, we determined the possible interaction between CK2 and Src kinases in SHRs. Treatment with PP2 alone and PP2 plus DRB similarly reduced the amplitude of NMDA puff-elicited currents of labeled PVN neurons in SHRs (n=7 neurons in each group; Figure 5C and 5D). The amplitude of NMDAR currents of labeled PVN neurons did not significantly differ between SHR brain slices treated with PP2 alone and PP2 plus DRB. These results suggest that although both CK2 and Src kinases regulate NMDAR activity of PVN presympathetic neurons, they probably affect different phosphorylation sites of NMDARs and their interacting proteins.
Src-Mediated NMDAR Activation in the PVN Plays a Role in the Maintenance of Sympathetic Vasomotor Tone in SHRs
We determined the functional significance of Src-mediated NMDAR activity in the PVN in controlling sympathetic vasomotor tone in SHRs. We did not perform PP2 injection in WKY rats because blocking NMDARs in the PVN has no effect on ABP or sympathetic nerve activity in normotensive rats. 2 The baseline integrated LSNA (averaged over 30 s) was 0.12±0.05 μV in SHRs, which was significantly higher in SHRs than in WKY rats (0.06±0.06 μV; P<0.05). We microinjected PP2 (40 pmol, 50 nL) 38 bilaterally into the PVN, which significantly decreased the LSNA and mean ABP of SHRs (n=7 rats; Figure 6A -6E). The LSNA and ABP started to decrease at a mean time of 3.1±0.5 minutes after PP2 injection, and this effect lasted for 29.7±1.8 minutes. In SHRs injected with PP2, subsequent microinjection of AP5 (1.0 nmol, 50 nL) 2,20 into the PVN failed to decrease LSNA, ABP, and HR. In contrast, microinjection of vehicle (0.5% dimethyl sulfoxide, 50 nL) into the PVN had no significant effect on ABP and LSNA in another set of SHRs (n=6 rats). Subsequent AP5 microinjection into the PVN significantly decreased LSNA and ABP in the SHRs receiving prior vehicle microinjection ( Figure 6A-6E ). These data suggest that the increased sympathetic vasomotor tone in SHRs is sustained by Src-mediated NMDAR activation in the PVN.
Discussion
The most salient finding of our study is that Src kinases critically contribute to the increased NMDAR activity, at both pre-and postsynaptic sites, of RVLM-projecting PVN neurons in a rat model of essential hypertension. Src is highly expressed in various brain regions 39, 40 and can interact with postsynaptic density proteins, such as PSD-95. [41] [42] [43] In the present study, we found that inhibition of Src kinase activity with PP2 significantly decreased the amplitude of evoked NMDAR-EPSCs and puff NMDA-induced currents in RVLM-projecting PVN neurons in SHRs but not in WKY rats. Although AMPARs can also be phosphorylated by the Src kinases, 44 we found that PP2 had no significant effect on the amplitude of mEPSCs or evoked AMPAR-EPSCs in PVN neurons in SHRs or WKY rats. Thus, Src regulation of AMPAR activity seems to be uninvolved in regulating glutamatergic input in the PVN in SHRs.
Src is also expressed at nerve terminals and is associated with synaptic vesicles. 45, 46 Presynaptic NMDARs in the hypothalamus and spinal cord are latent and not functionally active under physiological conditions. 18, 20 However, these receptors become tonically activated and promote synaptic glutamate release to PVN presympathetic neurons in hypertension. 17, 20 We found that PP2 significantly reduced the baseline frequency of mEPSCs of RVLM-projecting PVN neurons in SHRs. Furthermore, blocking NMDARs with AP5 decreased the frequency of mEPSCs in vehicle-treated, but not PP2-treated, brain slices of SHRs. Interestingly, we showed that PP2 produced no effect on puff NMDA-elicited currents or the mEPSC frequency in normotensive WKY rats. This differential effect of Src kinase inhibition on synaptic NMDAR activity is probably because of the low basal Src kinase activity in the PVN in WKY rats. Our findings suggest that increased Src kinase activity in the PVN may facilitate glutamate release by enhancing presynaptic NMDAR activity in SHRs. The sources of endogenous glutamate for tonic activation of presynaptic NMDARs in SHRs may come from the same terminals at which the NMDARs are expressed or from excitatory interneurons in the PVN that result from increased excitability and reduced synaptic inhibition. 34, 47 We showed that the Src protein level was significantly elevated in the PVN in adult SHRs compared with 4-weekold SHRs and adult WKY rats. However, the Src protein level in the RVLM, hippocampus, and frontal cortex did not significantly differ between WKY rats and SHRs, suggesting that Src upregulation is not a general phenomenon throughout all brain regions in SHRs. Because the Src protein level in the PVN was not altered by lowering ABP in SHRs with CGx, this suggests that Src upregulation in the PVN may not result from increased ABP but may instead contribute to hypertension development in SHRs. Altered tyrosine phosphorylation of NMDARs in the brain has been implicated in synaptic plasticity associated with depression 48 and fear learning. 49 Consistent with our in vitro slice recording data, we found that microinjection of the Src kinase inhibitor PP2 into the PVN significantly decreased LSNA and ABP in SHRs. Importantly, subsequent microinjection of AP5 reduced LSNA and ABP in vehicle-injected, but not in PP2-injected, SHRs. These in vivo data suggest that Src-mediated NMDAR activity in the PVN critically contributes to the elevated sympathetic vasomotor tone in SHRs. Increased Src kinase activity in SHRs may directly increase the phosphorylation level of certain tyrosine residues of NMDARs. For example, various tyrosine residues in GluN2A (Tyr-1292, Tyr-1325, and Tyr-1387) and GluN2B (Tyr-1252, Tyr-1336, and Tyr-1472) can be phosphorylated by Src kinases. 43, [50] [51] [52] [53] However, we cannot exclude the possibility that Src kinases increase NMDAR activity by phosphorylating tyrosine residues in NMDAR-interacting proteins, such as NADH dehydrogenase subunit 2.
54 CK2 is also involved in increased NMDAR activity of PVN presympathetic neurons in SHRs. 20 In this study, we found that intracellular application of an Src-activating peptide readily increased the NMDAR activity of RVLM-projecting PVN neurons. Although the potentiating effect of the Src-activating peptide on NMDAR activity was blocked by PP2, it was not affected by the CK2 inhibitor DRB. Furthermore, DRB had no further effect on NMDAR activity of PVN neurons that had already been reduced by PP2 in SHRs. Our data suggest that although both CK2 and Src kinases may contribute to increased NMDAR activity of PVN presympathetic neurons in SHRs through different phosphorylation sites, their roles are not mutually exclusive. Interestingly, PP2 has no effect on spinal NMDAR activity increased by CK2. 55 It has been shown that CK2 phosphorylates Ser-1480 residue in GluN2B, 56 whereas Src kinases phosphorylate Tyr-1325 in GluN2A. 48 Alternatively, NMDAR phosphorylation may involve a coordinated interaction between CK2 and Src kinases. In this regard, the catalytic subunits of CK2 can be directly tyrosine-phosphorylated by the Src kinases, leading to increased CK2 activity. 57 The overall activity of NMDARs in the PVN likely depends on their phosphorylation levels controlled by both CK2 and Src kinases. Nevertheless, the precise interaction between CK2 and Src kinases in the regulation of NMDAR activity of PVN presympathetic neurons in hypertension remains to be delineated.
Perspectives
We present novel evidence that increased Src kinase activity in the PVN plays a pivotal role in increased pre-and postsynaptic NMDAR activity of PVN presympathetic neurons in SHRs. Our study provides new insight into the molecular mechanism underlying elevated sympathetic vasomotor tone in an animal model of essential hypertension. The prevalence of resistant hypertension has been estimated to be 20% to 30%, 58 making it a common and challenging clinical problem. On the basis of our findings, we suggest that Src kinases are potential targets for treating patients with neurogenic hypertension. Further studies are needed to determine the dynamic changes in the Src kinases and their various isoforms in the PVN in different animal models of hypertension and to examine the long-term effect of the Src kinase inhibition in conscious hypertensive animals.
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